Product Description

The mu opioid receptor (μ-OR) is the most clinically significant subtype within the opioid receptor family, belonging to the G protein-coupled receptor class. It is widely and densely expressed in the central nervous system, primarily in brain regions involved in pain modulation and reward, such as the periaqueductal gray, spinal cord dorsal horn, thalamus, striatum, and locus coeruleus, and is also found on peripheral nerves and some immune cells. As the primary target for most clinical opioid analgesics (e.g., morphine, fentanyl), its activation produces potent analgesia, euphoria (reward effects), and sedation. However, it simultaneously leads to characteristic side effects like respiratory depression, constipation, tolerance, and addiction. Consequently, it is the central target for powerful pain relief, while its high addictive potential also underpins the biological basis of the global opioid crisis.

Screeningbio’s CHO-K1/Human μ cell line overexpress OPRM1 and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.